We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




HPV DNA Test Monitors Remission in Oral Cancer

By LabMedica International staff writers
Posted on 06 Nov 2018
A blood-based method has been developed to test patients with human papillomavirus-associated oral cancers for signs of remission or recurrence. More...
This approach would potentially allow doctors to more accurately and more easily identify which patients are free from cancer after radiation treatment, and which might be poised to recur.

Unlike liquid biopsy methods that search for non-viral tumor DNA mutations among the nucleic acid fragments circulating in the blood, the oral cancer assay relies on the fact that viral DNA, in this case from human papillomavirus, or HPV, is integrated in the genome of cancerous cells. Because the target, this viral DNA, is the same in all patients, a test does not require broad next-generation sequencing or the development of biomarker panels for each individual patient, as is being explored for the monitoring of other solid tumors like breast and colorectal cancer.

Scientists at the University of North Carolina at Chapel Hill (Chapel Hill, NC, USA) performed a prospective study that involved 89 patients with HPV-associated oral and throat cancers whose disease had not metastasized. All patients received definitive chemoradiation therapy and had some combination of PET/CT and chest X-ray scans beginning three months after treatment completion. Patients also had clinical exams every two to four months for the first two years of follow-up, and then every six months thereafter, and doctors took a blood sample at each visit to be tested for tumor-derived HPV DNA. The team has developed a strategy that uses a droplet digital PCR platform to detect and quantify circulating tumor HPV DNA representing several HPV types.

According to the authors, 70 of the 89 patients had undetectable levels of HPV DNA at every follow-up visit following the three-month, post-treatment scans. None of these 70 patients have so-far showed any sign of cancer recurrence. The remaining 19 patients developed a positive HPV DNA test result at some point between 7.8 months and 30.4 months after treatment. Eight of these were diagnosed with cancer recurrence. The other 11 have not yet shown evidence of disease and are being monitored with repeat blood tests and imaging. The team reported at the meeting that four of the individuals who had an initial positive test have now spontaneously cleared their HPV DNA signal, suggesting that they may have become free of disease, albeit later than others. This could represent immunosurveillance.

Bhisham S. Chera, MD, an associate professor and co-investigator of the study, said, “The ability to see a change in DNA levels over time and to resolve these unclear cases is a crucial aspect of the technology, a boon provided by the team's choice to use digital PCR.” The study was presented at the Annual Meeting of the American Society for Radiation Oncology held October 21-24, 2018, in San Antonio, TX, USA.

Related Links:
University of North Carolina at Chapel Hill


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.